Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy
Cabazitaxel, Docetaxel
NCT01308567, EudraCT2010-022064-12
Prostatic Neoplasm, Prostate Cancer
Phase 3
Datasets and document are available as per Sanofi Policy and criteria
August 2017